

Monday 23rd November 2026 - DAY I

AGENDA

geneTIGA achievements and the technology field

09:15 – 10:00 *Registration and welcome coffee*

10:00 – 10:10 **Opening and housekeeping**

10:10 – 10:40 **Welcome and Consortium overview**

Petra Reinke and Dimitrios Wagner

10:40 – 11:05 **IgA-TCRs moving to the clinic** (20 min + 5 min discussion)

Johanna Olweus

11:05 – 11:30 **Modernizing gene transfer – from random insertion to precise gene editing** (20 min + 5 min discussion)

Dimitrios Wagner or team

11:30 – 11:45 *Coffee break*

11:45 – 12:10 **Standards for genome editing assessment and safety** (20 min + 5 min discussion)

Toni Cathomen or Jacob Corn / team

12:10 – 12:35 **Identifying the patients in need: IgA pathophysiology** (20 min + 5 min discussion)

Katherine Bull

12:35 – 13:00 **Cell and Nano therapies in Organ Transplantation** (20 min + 5 min discussion)

Giuseppe Remuzzi - PHOENIX consortium

13:00 – 14:00 *Lunch*

14:00 – 14:25 **Patient perspective** (20 min + 5 min discussion)

Patient representative [TBD]

14:25 – 14:50 **Biomarkers for Cell Product ID Cards and Therapy Monitoring** (20 min + 5 min discussion)

CheckImmune (speaker TBD)

14:50 – 15:15 **CD19-CAR T cells without lymphodepletion for autoimmune disease** (20 min + 5 min discussion)

Jonathan Hogan, Cabaletta Bio

15:15 – 15:40 **In vivo CAR/TCR gene therapies** (20 min + 5 min discussion)

Matthias Bozza, CPTx GmbH [title TBD]

15:40 – 16:10 *Coffee break*

16:10 – 16:40 **Panel: technologies for next waves of T cell immunotherapies**

Jacob Corn, Jonathan Hogan, Matthias Bozza, Richard Day, Peter Mouritzen

Moderator: Dimitrios Wagner

Evening **Poster session**, rolling into dinner, followed by networking social

🕒 Tuesday 24th November 2026 - DAY II

AGENDA

Translation, patients and the EU funding landscape

09:30 – 09:40 **Welcome back**

09:40 – 10:05 **Personalised T-cell therapy for viral complications in immunosuppressed patients with and without transplantation** (20 min + 5 min discussion)

Britta Eiz-Vesper

10:05 – 10:30 **T-FITNESS project** (20 min + 5 min discussion)

Luca Gattinoni [title TBD]

10:30 – 11:00 *Coffee break*

11:00 – 11:25 **EU funding for ATMP development** (20 min + 5 min discussion)

Anna-Pia Papageorgiou / Mirko Lo-Cicero, HaDEA

11:25 – 12:10 **Panel: European innovation in the ATMP space**

Petra Reinke, Fadi Issa, Goran Josipović, Luca Gattinoni, EU representative;

Moderator [organized via InnActa]

12:10 – 12:25 **Closing remarks and consortium next steps** (20 min + 5 min discussion)

Petra Reinke and Dimitrios Wagner

12:25 – 12:35 **EAB statement**

12:35 – 14:00 *Farewell lunch and networking, end of open event*

14:00 – 15:30 **geneTIGA restricted meeting**

All talks are 20 minutes plus 5 minutes discussion unless otherwise noted. Draft programme – subject to confirmation.

🎯 POSTER SESSION - all partners - DAY I Evening

The following list is a preliminary plan of posters of geneTIGA Consortium.

Guest posters are welcome; abstract submission encouraged.

TU-BS: IgA binders

OUS: IgA-TCR discovery

Charité: IgA-specific CAR engineering – Roberts Karklins

Charité: Platforms to create CAR T cells (CD3ζ, CD3ε, STAR/HIT) – Jonas Kath

Charité: Base-editor mediate knock-ins for safer multiplex CAR T cells – Viktor Glaser

Charité: Modulating CAR-T homing via LNP-mRNA transfer of homing receptors – (TBD)

InnActa: Outreach and dissemination

UKLFR: Novel CAST-seq assay (Carla Fuster-Garcia);

UKLFR: Assay to predict the worst - clonal outgrowth

ETHZ: Off-target analysis for TCR-replacement and CAR integration (TRAC, TRBC1/2)

ETHZ: impact of DNA-PK inhibitors on gene editing outcomes

tissUse: Organ-on-a-chip models for IgAN

CheckImmune: Olink and scRNA-seq for patient monitoring – (TBD)

AU: Comparison of AAV vs dsDNA vs ssDNA – (Rasmus Bak TBC)

Potentially **AU + Charité:** Essential gene knock-in – maybe Christian

Charité: IgAN urine analysis for prediction of disease progression – Lennard Ostendorf

OUXF: Spatial omics and identification of patients in need of better treatments

OUXF: Humanised mouse models to study ATMPs in autoimmune disease and IgAN

GENOS: IgA glycosylation

GENOS: IgAN patient glycosylation

EKPF: Outreach efforts (IgAN Friends etc.)